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The flexible fiberoptic bronchoscope was introduced in Japan by Dr. Shigeto Ikeda in the midl 960s and became available .for clinical use in the
United States around i 970. The application of this
technique represents one of the most significant advances for the diagnosis and management of chest
diseases as it enables the physician to directly visualize the tracheobronchial tree and obtain diagnostic
specimens from regions of the lung previously inaccessible to the rigid bronchoscope. Except for subpleural lesions, fiberoptic bronchoscopy is the surgical procedure of choice in the evaluation of many
pulmonary lesions.' In addition, fiberoptic bronchoscopy plays a major therapeutic role in the evaluation of airway patency and elimination of retained
secretions.
The new Olympus® (BF-IT), Machida® (FBS6TL; FBS-6TL II), and Pen tax® (FB- l 9A) fiberoptic
bronchoscopes have larger channels measuring 2.6
mm in diameter as compared with older inodels
whose channels measure 1.8 to 2.2 mm. These larger
channels provide more effective suctioning and larger
biopsy specimens. 2
Indications for Fiberoptic Bronchoscopy
The following are accepted indications for fiberoptic bronchoscopy:
1. Any pulmonary lesion of uncertain nature.
Subpleural lesions are exceptions.
2. Retained bronchial secretions
3. Evaluation of airway patency
4. Miscellaneous:
a. hemoptysis in a patient with a normal
chest radiograph
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b. positive sputum cytology (that is, cancer)
in a patient with normal chest radiograph
c. small, peripheral foreign bodies in adults
d. patients with trauma or disease affecting
the cervical spine or jaw
e. patients on mechanical ventilators
Rigid bronchoscopy is preferred in the following
situations:
1. Severe pulmonary hemorrhage
2. Centrally located foreign bodies
3. Children requiring bronchoscopy
4. Tracheal stenosis, secondary to intrinsic or
extrinsic lesions
Risks and Contraindications
The following conditions are associated with increased risks during or following fiberoptic bronchoscopy:3
1. Hemoptysis (increased incidence of postbronchoscopy bleeding)
2. Bronchial asthma (danger of severe bronchospasm)
3. Uremia (danger of severe hemorrhage after
biopsy)
4. Immunosuppression (hazard of post-bronchoscopy infection)
5. Superior vena cava obstruction ( danger of
inducing laryngeal edema)
Poor patient cooperation, hypoxemia with an
arterial Po 2 that cannot be increased to 60 to 65 torr
with supplemental oxygen, uncorrected bleeding diathesis, acute respiratory acidosis of any degree, dangerous cardiac arrhythmias, recent (within six weeks)
acute myocardial infarction, and untreated active
pulmonary tuberculosis are contraindications for fiberoptic bronchoscopy. Terminally ill and aged patients with unstable vital signs should not have fiber169
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optic bronchoscopy performed. Severe pulmonary
hypertension and poor cardiopulmonary reserve are
relative contraindications.
Physician and Patient Preparations for Fiberoptic
Bronchoscopy
Prior to bronchoscopy, the endoscopist should
perform a history and physical examination, review
the chest radiographs, electrocardiograms, and blood
and urine tests . Arterial blood gas and spirometric
studies should be performed , if possible, prior to the
procedure. Coagulation studies (prothrombin time,
partial thromboplastin time, platelet count) should
be obtained. Three sputum smears for acid-fast organisms shouid be obtained in patients whose chest
radiographs are consistent with a diagnosis of tu,
berculosis. Finally, a signed operative permit should
be obtained from the patient.
Oxygen prophylaxis. All patients should receive
supplemental _,oxygen administered by nasal catheter
or cannula 5 L/ min . The Pao 2 may decrease as much
as 20 torr during and for several hours after bronchoscopy .4 This drop in oxygen tension appears to be
the result of multiple factors , including partial or
complete obstruction of the airways, filling of alveolar spaces with lavage or anesthetic solutions, and
suctioning. Therefore, all patients who have a reduced Pao 2 prior to the procedure should be given
supplemental oxygen for six to ten hours following
bronchoscopy.
Cardiac monitor. It is desirable that all patients
should have cardiac monitoring during bronchoscopy. The sudden development of an arrhythmia
or change in cardiac rate may suggest hypoxemia .
Recent studies suggest that fiberoptic bronchoscopy
does not consistently enhance preexisting ectopic
beats in patients with ischemic heart disease, therefore, the procedure is not contraindicated in patients
with stable angina . However, patients with coronary
heart disease should be monitored closely during the
procedure, since sinus tachycardia can develop,
which may cause ischemic events thus precipitating
arrhythmias.• The most important factor in the development of arrhythmias is not bronchoscopy itself,
but rather the underlying cardiopulmonary status of
the patient.
Preoperative orders. For a morning procedure,
NPO after midnight is required; for an afternoon
procedure, only a light liquid breakfast may be given .
Atropine 0.8 to 1.0 mg is given intramuscularly 30
minutes before bronchoscopy since this drug blocks
vasovagal reflexes and also reduces the amount of
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bronchial secretions. Depending upon the age, size
and clinical condition of the patient, morphine 7 .5 to
15 mg or meperidine 50 to 100 mg may be given
intramuscularly with the atropine. In our institution
we commonly use codeine 60 mg and atropine 0.8 to
1.0 mg 30 minutes prior to bronchoscopy. Patients
with severely reduced pulmonary function are given
only atropine.
Topical anesthesia is an extremely important
factor in securing patient acceptance and performing
a successful bronchoscopic examination. Lidocaine is
the most commonly used agent as it is effective and
safe provided a maximum dosage of 600 mg is not
exceeded during the procedure. This dose, which is
larger than that usually recommended, has been
found safe in a large series. In patients with severe
liver disease or congestive heart failure no more than
300 mg should be given.
The patient is first instructed to gargle with approximately 4 ml of 4% lidocaine for one to two
minutes, followed by spraying of the oropharynx and
the most widely patent nostril with 5 ml of 4% lidocaine via a #15 DeVilbus atomizer. Cotton balls
soaked in 4% lidocaine are applied to each piriform
sinus for one minute; then , via a curved cannula, 2.0
ml of I% lidocaine is administered over the vocal
cords.
With the patient either seated or supine the flex:
ible fiberoptic bronchoscope can be passed (with or
without an endotracheal tube) either transnasally or
transorally . The most commonly used technique for
diagnostic study in the United States is the direct
transnasal passage. (If fiberoptic bronchoscopy is
carried out through an endotracheal tube, the internal diameter of the tube should be 8.5 mm). The
distal six inches of the fiberoptic bronchoscope is
lubricated with lidocaine jelly. The bronchoscope is
then passed through the nostril and when in the
oropharynx, the tip angulated anteriorly to view the
larynx. If the patient begins coughing, 2 ml of 1%
lidocaine is administered over the vocal cords. The
patient is instructed to take a deep breath, and the
bronchoscope is passed into the trachea during this
inspiration. Additional small amounts of I% lidocaine are given as necessary to suppress coughing.
Once the bronchoscope is in the tracheobronchial
tree, examination of all five lobes can be performed in
approximately 10 to 15 minutes .
Biopsy Technique
A variety of biopsy instruments, primarily
brushes and forceps, are available for diagnosis of
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pulmonary lesions. In general, both brushes and forceps are used for all lesions. The brush biopsy is
obtained by moving the brush briskly back and forth
over the suspicious area. If the bronchoscope has
been introduced through the endotracheal tube, after
each biopsy, the brush is pulled back just inside the
bronchoscope and the bronchoscope removed from
the tracheobronchial tree. The brush is then advanced forward and smears are made on glass slides
which are placed in 95% alcohol.
Forceps biopsy can be used in the diagnosis of
local or diffuse pulmonary lesions. In diffuse lung
disease, the forceps is introduced into a small peripheral airway, usually in a lower lobe segment. The
forceps is opened in inspiration, the patient is instructed to exhale completely, the forceps is advanced
slowly about I cm, and at the end of an exhalation
the biopsy obtained. Following the removal of the
forceps, the distal end of the bronchoscope should be
wedged into the bronchial segment for one minute to
prevent possible bleeding. The biopsy specimen is
placed in a sterile tube filled with Ringer solution. In
general, three to four specimens, sometimes as many
as six to eight, are taken . Bronchial washings with 10
to 20 ml saline solution should also be obtained. The
specimens should be sent for cytology, smears, a nd
cultures for acid-fast organisms, fungi, and pathogenic organisms.
It is desirable to perform transbronchial biopsy
under fluoroscopic control if available. Because of
the possibility of bilateral pneumothorax, biopsies
are taken from one lung only.
In localized disease the forceps is introduced to
the lung lesion , then withdrawn I cm, opened, then
advanced until it touches the lesion; the forceps is
closed and the biopsy obtained. Prior to brush or
forceps biopsy, administration of 5 ml boluses of
I: 20,000 epinephrine over visible tumors or into distal airways (in cases of diffuse lesions) before biopsy,
reduces the incidence of pulmonary hemorrhage. A
total of 20 ml of I: 20,000 epinephrine solution can be
given over a period of 20 minutes, except in patients
with severe hypertension and serious arrhythmias. In
patients with uremia, brush or forceps biopsies
should not be done because of the possibility of severe hemorrhage; in those with a platelet count of less
than 50,000/ mm, 3 six to ten platelet packs should be
infused just prior to bronchoscopy. Finally, patients
with bronchial asthma are prone to develop severe
bronchospasm. They should be given bronchodilators and probably steroids prior to bronchoscopy.
Where centrally located visible carcinoma of the
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lung is present, the incidence of positive forceps
biopsy is about 97%. The overall yield in peripheral
carcinoma of the lung is about 60% to 70%, in metastatic carcinoma of the lung, about 30% to 40%, and
in diffuse lung diseases, the diagnostic yield ranges
from 62% to 79%. In stage I sarcoidosis, transbronchial biopsy will confirm the diagnosis in 50% to
60% of cases while in stage II and stage III sarcoidosis, diagnostic success is about 90%.
Complications of Fiberoptic Bronchoscopy
The overall complication rate is approximately
8%. The mortality rate is 0.1 %. The following are
potential complications:
I. Hypoxemia
2. Laryngospasm
3. Hemorrhage
4. Pneumothorax
5. Bronchospasm
6. Cardiac arrhythmias and acute myocardial
infarction
7. Post-bronchoscopy infection
8. Trauma due to endotracheal tube insertion
9. Hypoventilation

In summary, fiberoptic bronchoscopy is an extremely useful technique in the diagnosis and management of pulmonary diseases. It is quite safe and
comfortable for the patient and it permits examination of airways previously inaccessible to the endoscopist. However, physicians must evaluate each patient carefully. The procedure should be performed
by an experienced endoscopist who is familiar with
risk factors and proper indications for fiberoptic
bronchoscopy.
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